目的 探討丁螺環(huán)酮聯(lián)合阿立哌唑治療精神分裂癥焦慮癥狀的臨床療效。方法 采用隨機(jī)、抽樣與對照研究方法，選擇2014年2月-2017年1月在新鄉(xiāng)醫(yī)學(xué)院第二附屬醫(yī)院診治的精神分裂癥患者84例，伴有焦慮癥狀，根據(jù)信封隨機(jī)分組法分為觀察組與對照組各42例，對照組給予阿立哌唑治療，觀察組在對照組治療的基礎(chǔ)上給予丁螺環(huán)酮治療，兩組都治療觀察3個月。比較兩組的臨床療效及HAMA評分、皮質(zhì)醇水平變化，觀察兩組在治療期間出現(xiàn)的嗜睡、便秘、口干、頭暈等不良反應(yīng)情況。結(jié)果 觀察組的總有效率（95.2%）顯著高于對照組（81.0%），差異有統(tǒng)計學(xué)意義（P<0.05）。治療后觀察組、對照組的HAMA評分分別為（4.86±1.49）分和（7.98±2.10）分，都顯著低于治療前的（22.98±4.52）分和（23.87±3.10）分，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；觀察組也顯著低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。治療后兩組的皮質(zhì)醇水平顯著降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；觀察組治療后皮質(zhì)醇水平也顯著低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。治療期間兩組的嗜睡、便秘、口干、頭暈等不良反應(yīng)發(fā)生情況對比無顯著差異。結(jié)論 丁螺環(huán)酮聯(lián)合阿立哌唑治療精神分裂癥，能改善患者的焦慮癥狀和臨床療效，安全性也比較好。

Objective To investigate the clinical efficacy and the effect on HAMA score of buspirone in the adjuvant treatment of schizophrenia agitation. Methods Used a randomized, controlled study and sampling method, From February 2014 to January 2017, a total of 84 cases with schizophrenia agitation in our hospital were selected and were randomly divided into observation group and control group with 42 cases in each group accorded to the spirit of the envelope, the control group was given aripiprazole treatment, the observation group were given buspirone in the treatment based on the control group treatment, two groups were treated for 3 months. Results The total effective rates in the observation group and the control group were 95.2% and 81% respectively, and the observation group was significantly higher than that of the control group (P<0.05). After treatment, the HAMA scores in the observation group and the control group were (4.86 ±1.49) points and (7.98 ±2.10) points, respectively, which were significantly lower than those before treatment of (22.98 ±4.52) points and (23.87 ±3.10) points (P<0.05), and the observation group was also significantly lower than the control group (P<0.05). There were no significant difference in the incidence of somnolence, constipation, dry mouth, dizziness and other adverse reactions compared between the two groups. After treatment, the level of cortisol in the two groups were significantly lower than before treatment (P<0.05), and the level of cortisol in the observation group after treatment was also significantly lower than that of the control group (P<0.05). Conclusions buspirone in the treatment of schizophrenic agitation can promote the decline of HAMD score, thereby improving the therapeutic efficacy and safety. The mechanism may be related to the reduction of cortisol level.